Evaxion A/S (EVAX) Competitors

Evaxion A/S (NASDAQ:EVAX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Which has stronger valuation & earnings, EVAX or CARM?

Evaxion A/S has higher earnings, but lower revenue than Carisma Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$3.34M	1.22	-$10.57M	-$1.32	-2.21
Carisma Therapeutics	$19.63M	0.74	-$60.48M	-$1.56	-0.22

Is EVAX or CARM more profitable?

Carisma Therapeutics has a net margin of -254.28% compared to Evaxion A/S's net margin of -316.03%. Carisma Therapeutics' return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	-316.03%	-319.52%	-63.56%
Carisma Therapeutics	-254.28%	N/A	-192.17%

Which has more volatility and risk, EVAX or CARM?

Evaxion A/S has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.

Do analysts rate EVAX or CARM?

Evaxion A/S presently has a consensus target price of $10.00, suggesting a potential upside of 242.47%. Carisma Therapeutics has a consensus target price of $1.93, suggesting a potential upside of 456.68%. Given Carisma Therapeutics' higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Carisma Therapeutics	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.71

Do insiders and institutionals hold more shares of EVAX or CARM?

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media prefer EVAX or CARM?

In the previous week, Carisma Therapeutics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 3 mentions for Carisma Therapeutics and 2 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.89 beat Carisma Therapeutics' score of 0.45 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Carisma Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Carisma Therapeutics beats Evaxion A/S on 9 of the 17 factors compared between the two stocks.